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Background/Aims
Enteric dysbiosis is a risk factor for dietary proteins-associated intestinal alterations, contributing to the development of food 
allergies and the symptomatology of functional gastrointestinal disorders, mainly irritable bowel syndrome (IBS). We explored 
if a dysbiotic-like state, simulated by intraperitoneal administration of bacterial lipopolysaccharides (LPS), facilitates the sensitiza-
tion to a luminal antigen, ovalbumin (OVA), in rats.
Methods
Rats were exposed to oral OVA for 1 week, alone or with LPS. Thereafter, colonic histology, goblet cell density, mucosal eosi-
nophils and mucosal mast cell (MMC) and connective tissue mast cell (CTMC) were evaluated. Colonic expression (real-time 
quantitative polymerase chain reaction) of interleukins, IFN-1 and integrins was assessed to determine local immune responses. 
Luminal and wall adhered microbiota were characterized by fluorescence in situ hybridization. Colonic contractility (in vitro) 
served to assess functional changes associated to OVA and/or LPS.
Results
Neither OVA nor LPS, alone or combined, lead to structural alterations, except for a reduced goblet cell density in OVA-LPS- 
treated rats. MMC density was unaffected, while CTMC counts increased within the submucosa of OVA-LPS-treated animals. Marginal 
immune activation (IFN-1 up-regulation) was observed in OVA-LPS-treated rats. LPS induced a dysbiotic-like state characterized 
by decreased luminal bacterial counts, with a specific loss of clostridia. LPS facilitated Clostridium spp. wall adherence, an effect 
prevented by OVA. Colonic contractility was altered in OVA-LPS-treated animals, showing increased basal activity and enhanced 
motor responses to OVA.
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Conclusions
Changes in gut microbiota and/or direct effects of LPS might enhance/facilitate local neuroimmune responses to food antigens 
leading to motor alterations similar to those observed in IBS.
(J Neurogastroenterol Motil 2015;21:222-235)
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Introduction
Irritable bowel syndrome (IBS) is the most common func-
tional gastrointestinal disorder and is characterized by abdominal 
pain-discomfort associated with dysmotility and altered bowel 
habits.1 Although its underlying pathophysiology remains un-
clear, recent evidences suggest that IBS is due to a dysregulation of 
the brain-gut axis, with various peripheral alterations contributing 
to the exacerbation of the symptomatology. For instance, both 
changes in gut microbiota and adverse reactions to food allergens 
have been implicated in the pathogenesis of the disease.2-5
Intestinal food allergy-related mechanisms in IBS seem to in-
volve local mucosal responses to dietary antigens with activation 
of resident mast cells (MCs), rather than classical type-1 hyper-
sensitivity reactions.4,6 In this line, we have previously demon-
strated that long-term exposure to oral ovalbumin (OVA), with-
out adjuvants, results in a non-IgE mediated alteration of colonic 
motility in rats, an effect related to an excited-activated state of 
the tissue mucosal mast cells (MMCs). These OVA-mediated 
changes are reminiscent of those observed in IBS patients and in 
animal models of the disease.7-11
Gut commensal microbiota (GCM) has been implicated in 
the maintenance of the normal gastrointestinal hyporesponsive 
state to food antigens. For instance, results obtained in studies in 
infants with food allergy show a disturbed balance between bene-
ficial and potentially harmful bacteria in the large intestine and 
that supplementation with probiotics appears to alleviate the aller-
gic inflammation.12,13 Supporting these observations, results from 
animal models demonstrate a cause-effect relationship between 
dysbiotic states with reduced GCM and the development of aller-
gic responses to oral antigens.14,15 Overall, these data suggest that 
a disruption of the GCM might cause an impairment of the in-
testinal tolerogenic mechanisms, increasing the risk of food pro-
tein-induced immune activation and the development of food al-
lergy and/or IBS-like alterations.
The aim of the present study was to further explore the im-
pact of dysbiotic states of the colon in the generation of abnormal 
responses to dietary antigens. For this purpose, we treated rats 
with low doses of bacterial lipopolysaccharides (LPS).16 Simulta-
neously, animals were exposed orally to an allergic protein, OVA. 
The potential facilitatory effects of LPS towards OVA sensitiza-
tion were studied in vitro by assessing spontaneous colonic con-
tractility and the contractile responses elicited by the presence of 
the antigen (OVA). To further understand the potential role of 
GCM in the functional alterations observed, changes in the co-
lonic microbiota and bacterial wall adherence were determined by 
fluorescence in situ hybridization (FISH). Finally, to gain in-
sight into the immune nature of the IBS-like responses related to 
dietary antigens, we assessed local changes in cytokines expression, 




Adult (9-week-old), specific pathogen free (SPF), Sprague- 
Dawley (SD) male rats were used (Charles River, Les Oncins, 
France). Animals had free access to water and were fed with a 
standard diet (145 g/kg protein, 40 g/kg fat, 45 g/kg fiber and 
13.4 kJ/g; free of traces of ovalbumin or any other egg derivative; 
Teklad Global 14% Protein Rodent Maintenance Diet 2014, 
Harlan Interfauna Iberica S.A.). During all the experiment, rats 
were maintained under conventional conditions in a light (12 
hour/12 hour light-dark cycle) and temperature controlled 
(20-22oC) room, in groups of 2 per cage. Animals were acclimat-
ized to the new environment for 1 week before starting any ex-
perimental procedure. All the experimental protocols were ap-
proved by the Ethical Committee of the Universitat Autònoma 
de Barcelona and the Generalitat de Catalunya (protocols 1010 
and 5351, respectively).
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Exposure to Oral Ovalbumin and Treatment 
With Lipopolysaccharides
Rats were exposed to OVA by a daily oral gavage (10 mg/ 
mL, 1 mL/rat, n = 15) during a one week period. A group of rats 
were used as controls, in which the same exposure protocol was 
followed but OVA solution was replaced by saline (1 mL/rat, n = 
15). In parallel, a subgroup of vehicle- and OVA-exposed rats (n 
= 8 for each) was treated intraperitoneally with LPS (100 
g/kg/day for 7 days). The rest of the rats (7 vehicle- and 7 
OVA- exposed animals) received the vehicle for LPS (1 mL/ 
kg/day for 7 days). Animals were examined for clinical signs and 
body weight changes on a daily basis (at the time of treatment) and 
were euthanized by decapitation after 24 hours of the last treatment. 
At the time of euthanasia, tissue samples from the colon were col-
lected for functional studies (organ bath studies) or either fixed in 
4% paraformaldehyde or Carnoy’s solution, for immunohisto-
chemical and FISH studies respectively, or frozen in liquid nitrogen 
and stored at −80oC until analysis.
Organ Bath Studies
Full thickness preparations were obtained from the mid por-
tion of the colon, cut 1 cm long and 0.3 cm wide and hung, ori-
ented to record circular muscle activity, for organ bath studies. 
Strips were mounted under 1 g tension in a 10-mL organ bath 
containing carbogenated Krebs solution (95% O2 and 5% CO2) 
maintained at 37 ± 1oC. The composition of Krebs solution was 
(in mmol/L): 10.10 glucose, 115.48 NaCl, 21.90 NaHCO3, 
4.61 KCl, 1.14 NaH2PO4, 2.50 CaCl2, and 1.16 MgSO4 (pH 
7.3-7.4). One strip edge was tied to the bottom of the bath and 
the other one to an isometric force transducer (Harvard VF-1 
Harvard Apparatus Inc, Holliston, MA, USA). Output from 
the transducer was fed to a PC through an amplifier. Data were 
digitalized (25 Hz) using Data 2001 software (Panlab, Barcelona, 
Spain). Strips were allowed to equilibrate for about 1h. After this 
period, contractile responses to carbachol (CCh; 0.1-10 M), 
bovine serum albumin (BSA; 0.1%) and OVA (0.1%) were 
assessed. For CCh, cumulative concentration-response curves, 
with a 5-minute interval between consecutive doses, were con-
structed. For BSA or OVA, spontaneous activity was recorded 
during a 15-minute period after the addition of the protein.
To determine the spontaneous contractile activity, the area 
under the curve (AUC) was measured (in grams) over a 15-minute 
period. To assess the effects of CCh, the peak response, from the 
basal tone, was measured after each concentration tested. For as-
sessing the response to BSA or OVA exposure, the AUC was 
measured for a 10-minute period before the addition of the pep-
tide and compared with the 10 minutes AUC measured during 
the 5- to 15-minute period post-addition. 
Histology, Immunohistochemistry and Cell 
Counting
Paraformaldehyde-fixed tissue samples were processed rou-
tinely for paraffin embedding, and 5-m thick sections were ob-
tained for hematoxylin and eosin (H&E), toluidine or alcian blue 
staining or for immunohistochemistry. All the preparations were 
viewed with an Olympus CH30RF200 microscope.
H&E-stained colonic sections were used for histological ex-
amination of the tissue and also for assessing eosinophil infiltra-
tion, as determined by counting the number of eosinophils in 20 
non-adjacent fields of colonic mucosa (×600). 
MMCs were identified by immunodetection of rat mast cell 
protease II (RMCP II) using a monoclonal antibody anti- 
RMCP II (Moredun Animal Health, Edinburgh, UK). The 
secondary antibody was a biotinylated horse antimouse IgG 
(BA-2000; Vector Laboratories, Burlingame, CA, USA). 
Detection was performed with avidin/peroxidase kit (Vectastain 
ABC kit; Vector Laboratories). Specificity of the staining was 
confirmed by omission of the primary antibody. Sections were 
counterstained with 1% toluidine blue solution (pH 0.5) for 20 
minutes, which served to identify CTMCs. For MMCs quanti-
fication, at least 20 non-adjacent fields (×400) of colonic mucosa 
were randomly selected and the number of RMCP II-immuno-
positive cells determined manually. CTMCs were identified by 
the presence of toluidine blue-stained metachromatic granules in 
their cytoplasm. Total number of toluidine blue-stained cells in 
the preparation was determined and then normalized for the sur-
face area of the tissue section. To identify goblet cells, colonic tis-
sue sections were stained with Alcian Blue pH 2.5/Periodic Acid 
Schiff (AB 2.5/PAS kit; Bio-Optica, Milano, Italy) in order to 
specifically stain neutral (pink) and acidic (blue) mucins. Colonic 
goblet cells were counted in 20 longitudinally-oriented vil-
lus-crypt units. Length of the villus-crypt unit was determined to 
obtain goblet cells density (number of cells/mm). In all cases, cell 
counting was carried out on coded slides to avoid bias.
Rat Mast Cell Protease II Quantification
Protein was extracted from colonic tissue samples using lysis 
buffer (50 mM HEPES, 0.05% Triton X-100, 0.0625 mM 
PMSF, and the Mini Complete protease inhibitor Roche) and 
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Table 2. TaqMan Gene Expression Assays
Protein Gene symbol Assay reference
Inflammatory markers
    IL-6 Il6 Rn01410330_m1
    IL-13 Il13 Rn00587615_m1
    IL-10 Il10 Rn00563409_m1
    IL-12 (subunit beta) Il12b Rn00575112_m1
    Interferon alpha-1 (IFN-1) Ifna1 Rn02395770_g1
Markers of host-microbial interactions
    Integrin-1 Itgb1 Rn00566727_m1
    Integrin-2 Itga2 Rn01489315_m1
    Resistin-like molecule beta (RELM-) Retnlb Rn01439306_m1
Reference gene
    Actin Actb Rn00667869_m1
Table 1. Probes Used for Fluorescent In Situ Hybridization and Hybridization Conditions
Probe Sequence (5’ → 3’) Target Hybridization temp (oC)
EUB 338 GCTGCCTCCCGTAGGAGT Bacteria 50
NON 338 ACATCCTACGGGAGGC Non bacteria (negative control) 50
EREC 482 GCTTCTTAGTCAGGTACCG Clostridium cluster XIVa 50
ENT-D TGCTCTCGCGAGGTCGCTTCTCTT Enterobacteria 50
BIF 164 CATCCGGCATTACCACCC Bifidobacterium spp. 50
RMCP II concentration was determined by ELISA using a 
commercial kit (Moredun). Total protein was determined using 
the Bradford assay kit (BIO-RAD, Hercules, CA, USA). 
Bacterial Identification by Fluorescence In 
Situ Hybridization 
For FISH, oligonucleotide probes (Biomers, Ulm/Donau, 
Germany and Tib Molbiol, Mannheim, Germany) with a 5’-Cy3 
(carbocyanine) dye were used (5 ng/L). The bacterial groups 
characterized and the specific probes used are specified in Table 1. 
In situ hybridization of bacteria in the luminal colonic con-
tent was performed on glass slides, as previously described by 
us.17-19 Samples were hybridized for 16 hours by addition of the 
hybridization buffer (20 mM Tris-HCl, 0.9 M NaCl, 0.1% 
SDS at pH 7.2) and thereafter washed with the washing buffer 
(20 mM Tris-HCl, 0.9 M NaCl at pH 7.2) for 30 minutes. 
4',6-diamidino-2-phenylindole (DAPI) served as a control signal 
in all samples. Hybridized slides were viewed under oil im-
mersion, using a Carl Zeiss Axioskop 40 FL epifluorescence mi-
croscope (filter for Cy3) equipped with a digital camera (Zeiss 
AxioCam MRm; Carl Zeiss MicroImaging GmbH, Jena, 
Germany) for obtaining digital images (Zeiss AxioVision Release 
4.8.1; Carl Zeiss MicroImaging GmbH, Jena, Germany). For 
quantification of bacteria, 20 randomly selected fields were pho-
tographed, the number of hybridized cells counted using the 
CellC software20 and the mean value obtained. 
To assess bacterial adherence to the colonic wall, sections from 
Carnoy-fixed tissues were hybridized in the same conditions. 
Slides were viewed under oil immersion and 20 randomly se-
lected fields were photographed. Analysis of the images was per-
formed manually by 3 independent researchers that observed the 
pictures and localized hybridized bacteria within the mucus layer 
or attached to the epithelial surface. A coincidence between 2 out 
of the 3 observers in bacterial location in at least three out of the 
20 pictures observed was required to decide that there was bacte-
rial attachment to the epithelium.18 All procedures were per-
formed on coded slides, to avoid bias. 
RNA Extraction and Quantitative Real-time 
Polymerase Chain Reaction
Total RNA was extracted from frozen colonic samples by ho-
mogenization in Trizol reagent (Ambion, Austin, Texas, USA) 
followed by isopropanol precipitation and quantification by Nanodrop 
(Nanodrop Technologies, Rockland, DE, USA). For cDNA 
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synthesis, 1 g of RNA was reverse-transcribed in a 20 L re-
action volume using a high capacity cDNA reverse transcription 
kit (Applied Biosystems, Foster City, California, USA). Real- 
time quantitative polymerase chain reaction (RT-qPCR) was 
performed to determine mRNA levels of inflammatory markers, 
integrins and resistin-like molecule-beta (RELM-beta) in the 
colon. The TaqMan probes listed in Table 2 were used (Applied 
Biosystems). The PCR reaction mixture was incubated on a 7900 
real-time PCR system (Applied Biosystems) for 40 cycles (95oC 
for 15 seconds, 60oC for 1 minute). B-Actin expression served as 
an endogenous control for normalizing the mRNA levels of the 
target gens. Expression levels were analyzed by the comparative 
Ct method (2-ΔΔCT) using the vehicle-vehicle group as the 
calibrator.
Chemicals
OVA (Grade V; A5503), BSA (A9085) and LPS (LPS 
from Escherichia Coli 055:B5; 62326) were purchased from 
Sigma-Aldrich (St.Louis, MO, USA) and were dissolved in sal-
ine solution. Carbachol (Sigma-Aldrich) was dissolved in dis-
tilled water at a 10−1 M, further dilutions were prepared in dis-
tilled water.
Statistical Methods
All data are expressed as mean ± SEM; except for bacterial 
counts that are expressed as media (interquartile range) ± SD. A 
robust analysis (one iteration) was used to obtain mean ± SEM 
for RT-qPCR data. Comparisons between multiple groups were 
performed by a one-way or a two-way ANOVA, as appropriate, 
followed when necessary by a Fisher’s least significant difference 
(LSD) post hoc test to detect differences between experimental 
groups. P-values ＜ 0.05 were considered statistically significant.
Results
Animal Monitoring
Exposure to oral OVA alone during 1 week did not affect 
body weight compared to animals receiving saline. Addition of 
LPS produced a transitory loss of body weight, evident only dur-
ing the first day of treatment. LPS-induced body weight loss was 
similar in vehicle-LPS (5.24 ± 1.01%; P ＜ 0.05 vs vehicle-ve-
hicle group) and OVA-LPS-treated groups (4.05 ± 0.77%; P 
＜ 0.05 vs OVA-vehicle group). Thereafter, the repeated intra-
peritoneal administration of LPS did not longer affect body 
weight and similar weight gain was observed across experimental 
groups. No other clinical signs were observed. 
Colonic Histology 
Histological examination of the colon revealed no substantial 
effects associated to treatments, without evidences of tissue dam-
age or inflammatory-like changes. The number of eosinophils in-
filtrating the colonic mucosa was similar across experimental 
groups (Fig. 1A). Quantification of goblet cells in AB-PAS- 
stained sections revealed that LPS treatment was associated to a 
diminished cell density, as assessed by a two-way ANOVA, 
reaching statistical significance in OVA-LPS-treated rats (122.7 
± 3.8 cells/mm; P ＜ 0.05 vs vehicle-vehicle: 153.8 ± 4.0 
cells/mm; Fig. 1B). Animals exposed to OVA alone also showed 
a tendency for a decrease in the relative abundance of goblet cells 
(133.8 ± 6.75 cells/mm; P = 0.050 vs vehicle-vehicle; Fig. 1B). 
In vehicle-vehicle-treated animals, combined AB-PAS staining 
revealed that nearly all the goblet cells of the colonic mucosa con-
tained acidic mucins (blue staining), with very few goblet cells 
showing mixed or neutral mucins (purple and pink staining, re-
spectively). Relative abundance of acidic, mixed and neutral mu-
cins was not affected by OVA or LPS or their combination.
Mast Cells Counts and Rat Mast Cell 
Protease II Content
Colonic MMC counts remained unaltered after one week 
exposure to oral OVA (OVA-vehicle: 5.26 ± 0.90 cells/field; P 
＞ 0.05 vs vehicle-vehicle: 5.80 ± 2.18 cells/field; Fig. 1C). 
Addition of LPS had no effect on the colonic density of MMCs 
(Fig. 1C). Similarly, colonic content of RMCP II was unaffected 
by OVA (OVA-vehicle: 0.55 ± 0.21 ng/g protein; P ＞ 0.05 vs 
vehicle-vehicle: 0.56 ± 0.23 ng/g protein) and remained un-
altered after LPS treatment (Fig. 1D).
CTMCs, identified by its metachromatic granules, were 
mainly localized in the submucosa of the rat colon, with a rela-
tively low density in control conditions (2.73 ± 0.29 cells/field; 
Fig. 1E and 2). Neither OVA nor LPS, per se, affected CTMCs 
counts. However, in OVA-LPS-treated animals the counts of 
CTMCs were increased by 2-fold when compared with the sepa-
rate treatments or the vehicle-vehicle group (P ＜ 0.05; Fig. 1E 
and 2). 
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Figure 1. Colonic density of eosinophils (A), goblet cells (B), mucosal 
mast cells (C), RMCP II content (D), and connective tissue mast cells 
(E) in the different experimental groups. Data are mean ± SEM of 4-8 
animals per group. *P ＜ 0.05 vs vehicle-vehicle group. &P = 0.050 vs 
vehicle-vehicle group. +P = 0.091 vs vehicle- vehicle group.
Characterization of Luminal and 
Wall-adhered Microbiota
In vehicle-vehicle-treated animals, total bacterial counts in the 
luminal content of the colon, determined by FISH as EUB338- 
positive cells and confirmed by DAPI staining, were within the 
margins previously described by us (3.74 × 1010 ± 1.16 × 1010 
cells/mL; Fig. 3).17,19 Total bacterial counts were not altered by 
the administration of OVA alone (2.90 × 1010 ± 6.10 × 109 
cells/mL; P ＞ 0.05 vs vehicle-vehicle; Fig. 3). However, treat-
ment with LPS diminished by 50% total bacterial counts vs ve-
hicle-vehicle values, irrespective of the coadmnistration of OVA 
(LPS-vehicle: 1.75 × 1010 ± 3.10 × 109 cells/mL; LPS-OVA: 
1.62 × 1010 ± 1.84 × 109 cells/mL; both P ＜ 0.05 vs ve-
hicle-vehicle; Fig. 3). This effect was further confirmed by sim-
ilar results obtained in DAPI-positive nuclei counts (Fig. 3). 
Independently of the changes in total bacterial counts, LPS 
and OVA resulted in states of dysbiosis, affecting selectively the 
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Figure 2. Representative microphotographs showing connective tissue mast cells (CTMCs) in toluidine blue-stained colonic slices from 
vehicle-vehicle- (A), ovalbumin (OVA)-vehicle- (B), lipopolysaccharide (LPS)-vehicle- (C), and LPS-OVA-treated (D) rats. The arrows indicate 
CTMCs in the submucosa, as identified by the presence of toluidine blue-stained metachromatic granules in their cytoplasm. Notice the increased 
density of the CTMC population in the colonic submucosa of LPS-OVA-treated animals (D). 
Clostridium cluster XIV or C. coccoides group (EREC482 probe). 
Overall, Clostridium spp. was the most abundant strain, irre-
spective of the treatment considered. Exposure to oral OVA 
alone or LPS alone decreased Clostridium spp. counts in similar 
proportion (OVA-vehicle: 7.83 × 109 ± 1.41 × 109 cells/mL; 
vehicle-LPS: 7.53 × 109 ± 1.19 × 109 cells/mL; P = 0.072 and 
P = 0.050 vs vehicle-vehicle, respectively; Fig. 3). The combina-
tion of both treatments resulted in a further reduction in Clostridium 
spp. counts to 4.26 × 109 ± 4.03 × 108 cells/mL (P ＜ 0.05 vs 
vehicle-vehicle; Fig. 3). Other bacterial groups assessed, namely 
Bifidobacterium spp. (BIF164 probe) and Enterobacteria (ENT- 
D probe) were not affected by either OVA, LPS or their 
combination.
In vehicle-vehicle-treated animals, bacterial adherence to the 
colonic epithelium was relatively low and similar for all the bacte-
rial groups assessed (by 20% incidence; Fig. 3). Treatment with 
OVA, did not affect the incidence of bacterial wall adherence. 
However, LPS showed a tendency to favour the adherence of 
Bifidobacterium spp. (incidence: 35%) and Clostridium spp. (incidence: 
50%) (Fig. 3 and 4). The combination of OVA and LPS com-
pletely prevented the adherence of Clostridium spp. (0% in-
cidence) without affecting the adherence of Bifidobacterium spp. 
(incidence: 35%). 
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Figure 3. Composition of the luminal microbiota and incidence of bacterial wall adherence, as assessed by fluorescence in situ hybridization. Bacterial
counts are median (interquartile range) ± SD, 7-8 animals per group. *P ＜ 0.05 vs vehicle-vehicle group. +P = 0.050 vs vehicle-vehicle group. &P
= 0.072 vs vehicle-vehicle group. Incidence of bacterial wall adherence (bottom right corner): data represent the percentage of animals showing 
bacterial wall adherence for the different bacterial groups assessed. DAPI, 4',6-diamidino-2-phenylindole; OVA, ovalbumin; LPS, lipopolysaccharide.
Expression of Inflammatory Markers and 
Markers of Host-bacterial Interactions
In control conditions (vehicle-vehicle-treated animals), co-
lonic mRNA expression of pro-inflammatory (IFN-1, IL-6, 
IL-12, and IL-13) and anti-inflammatory markers (IL-10) was 
relatively low, but within detectable ranges in all samples. 
Overall, relative expression of cytokines was: IFN-1 ＞ IL-10 
＞ IL-12 ＞IL-6/IL-13.
Exposure to oral OVA alone did not affect cytokines ex-
Ferran Jardí, et al
Journal of Neurogastroenterology and Motility 230
Figure 4. Representative colonic tissue images showing wall adherence of Clostridium spp. (EREC 482 probe) in the different experimental groups. 
White arrowheads indicate hybridized bacteria attached to the colonic epithelium. OVA, ovalbumin; LPS, lipopolysaccharide.
pression; with the exception of IL-12, which was slightly 
up-regulated although statistical significance was not reached. 
Similarly, LPS alone had minor effects on cytokines expression, 
with only a tendency (P = 0.060) to increase colonic IL-6 levels 
(Fig. 5). However, combined treatment with OVA and LPS re-
sulted in a 2-fold increase in the expression of IFN-1 (Fig. 5). 
In control conditions, markers of host-bacterial interactions, 
namely integrin-1, integrin-2, and RELM-, were moder-
ately expressed. Relative expression levels were: integrin-1 ＞ 
integrin-2 ＞ RELM-. OVA tended to down-regulate in-
tegrin-2, particularly in animals co-treated with LPS (Fig. 5).
Colonic Contractility In Vitro
Spontaneous colonic contractile activity was similar in ve-
hicle-vehicle- and OVA-vehicle-treated animals ([AUC in 15 
minutes] OVA-vehicle: 39.81 ± 4.88 g; vehicle-vehicle: 34.19 
± 2.39 g; P ＞ 0.05; Fig. 6A). A two way ANOVA analysis re-
vealed that the challenge with LPS had a significant effect (P = 
0.043) enhancing contractile activity both in vehicle-LPS- and 
OVA-LPS-treated rats (Fig. 6A). However, further post hoc test 
(Fisher’s least significant difference) found no differences be-
tween specific groups. 
In vehicle-vehicle-treated animals, CCh elicited contractile 
responses in a concentration-dependent manner. Neither OVA 
nor LPS, alone or in combination, affected the contractile re-
sponses to CCh (Fig. 6B).
The spontaneous contractile activity of tissue samples ob-
tained from vehicle-vehicle-treated animals was not affected by 
the direct addition of OVA to the organ bath. Similarly, in tissues 
from animals exposed to oral OVA during one week, direct ex-
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Figure 5. Colonic expression of inflammatory markers and markers of host-bacterial interactions. Each symbol represents an individual animal, the 
horizontal lines with errors represent the mean ± SEM. *P ＜ 0.05 vs vehicle-lipopolysaccharide (LPS) and ovalbumin (OVA)-vehicle group. #P =
0.082 vs vehicle-vehicle group. +P = 0.091 vs vehicle-vehicle group. &P = 0.075 vs vehicle-LPS group. RELM, resistin-like molecule.
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Figure 6. Colonic contractility in vitro. (A) Colonic spontaneous contractile activity (AUC in 15 minutes) in the different experimental groups. Data 
are mean ± SEM; n = 4-6 per group. (B) Concentration-response curves for carbachol. Data show the maximal response to each concentration of 
carbachol added to the bath and is represented as mean ± SEM (symbols) and non-linear regression curves. n = 4-6 per group. (C) Colonic contractile 
responses to ovalbumin (OVA) challenge. Data represent the net change in contractile activity during the 5-15 minute period after addition of OVA 
to the organ bath (taking as basal the contractile activity during the 10 minutes previous to OVA addition). Each symbol represents an individual 
animal, the horizontal lines with errors represent the mean ± SEM (n = 4-7 per group). The broken horizontal line corresponds to the mean + 2 ×
SEM. *P ＜ 0.05 vs vehicle-LPS group. #P = 0.092 vs OVA-vehicle group. (D) Representative tracings showing the effects of OVA and bovine 
serum albumin (BSA) challenge on spontaneous colonic contractility in an OVA-lipopolysaccharide (LPS)-treated animal. Notice the increase in the 
magnitude and frequency of colonic contractions after addition of OVA to the organ bath, an effected non-observed after the addition of BSA.
posure to OVA was without effect. However, OVA challenge on 
tissues obtained from OVA-LPS-treated rats resulted in an in-
crease (P ＜ 0.05) in the frequency and magnitude of the sponta-
neous contractile activity (Fig. 6C and 6D). Regardless the ex-
perimental group considered, direct addition of a BSA solution to 
the organ bath did not affect colonic spontaneous contractile 
activity.
Discussion
Dietary antigens and gut microbiota are potential factors con-
tributing to the pathophysiology of IBS. In this study, we show an 
interaction between a dietary antigen (OVA) and microbial com-
ponents that leads to a situation of dysbiosis together with an al-
tered colonic contractility, mimicking some of the features de-
scribed in IBS patients. Our results indicate that LPS favors the 
colonic sensitization to OVA, thus suggesting that alterations of 
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the commensal microbiota and the gut host-microbiotal inter-
actions might be factors facilitating the intestinal (colonic) sensi-
tization against dietary antigens and the development of IBS-like 
states.
We previously showed that rats exposed to oral OVA, with-
out adjuvants, during a 6-week period, develop a colonic con-
tractility dysfunction, resembling that observed in IBS patients 
and other animal models of the disease.7-11,21 However, repeated 
exposure to low doses of a dietary antigen might lead to a process 
of oral tolerance.22,23 Therefore, in the present work, we assessed 
the effectiveness of a shorter exposure period to high doses of oral 
OVA in the induction of IBS-like colonic motor alterations. 
Results obtained show that colonic contractility remained un-
altered after 1-week exposure to 10 mg of OVA, thus suggesting 
that, in contrast to long-term exposure, sensitization to oral anti-
gens induced by few administrations might require the presence 
of facilitatory elements, such as adjuvants.24 We also explored if 
GCM might represent a potential factor favoring the induction 
of adverse reactions to food antigens. Administration of low- 
doses of LPS, which mimics a gram-negative bacterial overload, 
resulted in a specific dysbiosis of the colon. In addition, when 
combined with oral OVA, LPS induced an enhanced colonic 
contractility to the direct addition of the antigen to the organ 
bath, thus indicating a sensitization of the tissue to OVA. These 
altered responses of the colon are reminiscent of the exacerbated 
symptomatology reported in a subgroup of IBS patients after the 
ingestion of certain foods, reinforcing the hypothesis that adverse 
reactions to dietary components might be a contributing factor to 
the pathophysiology of the disease.25 Moreover, results shown 
here support the view that gut microbiota might facilitate the sen-
sitization process to luminal antigens, thereby representing a fac-
tor leading to the development or the exacerbation of symptoms 
in IBS.
Dietary-related IBS-like responses have been associated, 
both in patients and animal models, to local mechanisms of the 
colonic mucosa rather than a systemic reaction, more character-
istic of food allergies.4,6,7 In agreement with these observations, in 
this study, OVA-induced altered contractility in OVA-LPS- 
treated rats was neither related to the presence of circulating spe-
cific IgEs (unpublished results) nor to the altered expression of 
pro- (IL-6 and IL-13) or anti-allergic (IL-12 and IL-10) cyto-
kines.26,27 However, these animals showed a specific up-regu-
lation of IFN-1, similar to that observed in IBS-like states.28,29
Colonic motor changes after long term exposure to oral OVA 
are related to an excited-activated state of MMCs.21 Moreover, 
MMCs have been directly implicated in the pathophysiology of 
IBS, although their exact role remains unclear.30-32 Here, no 
changes in MMC density or their excited-activated state was ob-
served after a 1-week OVA exposure, with or without LPS. 
However, CTMC counts were increased in the submucosa of 
OVA-LPS-treated animals, while unaffected in animals treated 
only with OVA or LPS. Although the potential involvement of 
CTMCs in IBS has been less studied, several observations sug-
gest that they could act also as effector cells leading to functional 
alterations within the gut. For instance, we have described a sim-
ilar increase in CTMCs in the jejunum of Trichinella spiralis-in-
fected rats, an accepted model of post-infectious IBS that also 
courses with dysmotility.33 Moreover, CTMC counts are in-
creased in mice with food allergy34,35 and the degranulation of 
CTMCs excites the intestinal smooth muscle in vitro.36 Although 
further in deep studies are required, these observations suggest 
that submucosal CTMC could be taking part in the altered con-
tractile responses observed in OVA-LPS-treated rats.
Gut microbiota is a dynamic component of gastrointestinal 
homeostasis. Epidemiological and clinical data support the hy-
pothesis that significant perturbations of the GCM can disrupt 
the mechanisms of oral tolerance leading to allergic responses.37 
In agreement, in the current study, low doses of LPS facilitated 
the sensitization to oral OVA at the same time that induced 
changes in GCM (an overall decrease in luminal bacterial counts 
with a specific dysbiotic state characterized by a loss of clostridia). 
At the same time, LPS favored the adherence of Clostridium spp. 
to the colonic wall. A cause-effect relationship between adherence 
and luminal microbiota can be suggested from these changes. It is 
feasible to speculate that increased host-bacterial interactions, 
driven by the adherence of clostridia, might trigger a local re-
sponse that results in the dysbiotic-like state observed when as-
sessing the luminal microbiota. The apparent mismatch between 
adherence and luminal bacterial counts is similar to that observed 
previously in other models of dysbiosis and suggests that, besides 
the absolute number of bacteria, other factors modulate host-bac-
terial interactions.18 Nevertheless, we did not observe changes in 
the overall expression of adhesion molecules or RELM-beta, im-
portant components facilitating host-bacterial interactions within 
the gut. From the present studies, we cannot state that the ob-
served changes in the microbiota are relevant in the facilitatory ef-
fects of LPS towards OVA sensitization. However, this hypoth-
esis is supported by previous results that demonstrate a direct re-
lationship between altered states of GCM and increased suscepti-
bility to sensitization to oral dietary antigens.14 
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Abnormal intestinal responses to dietary antigens have been 
related in part to an altered epithelial barrier function.38 Indeed, 
altered gut microbiota is able to favor sensitization towards diet-
ary antigens throughout changes in epithelial permeability.38 
Here, although not directly assessed, it is feasible to assume the 
presence of an altered barrier function as the doses and pattern of 
administration of LPS were similar to other studies demonstrat-
ing an increased epithelial permeability.39,40 In addition, adher-
ence of Clostridium spp. to the colonic epithelium, favored by 
LPS, could be a contributing factor in the alteration of the barrier 
function and the subsequent sensitization to OVA. Surprisingly, 
in OVA-LPS-treated rats no adherence of Clostridium spp. was 
observed (0% incidence). This might be associated to the pres-
ence of colonic hypercontractility generated by the presence of 
OVA in a state of LPS-induced enhanced sensitization. In these 
conditions, increased colonic motility might difficult the inter-
action between luminal bacteria and the epithelium, preventing 
bacterial adherence. In agreement with this hypothesis, we ob-
served that direct addition of OVA to the organ bath only in-
creased colonic contractile activity in tissues from OVA-LPS- 
treated animals. Moreover, this effect on bacterial dynamics 
might be potentiated by the enhanced mucus release present in 
OVA-LPS-treated rats, as suggested by the reduced density of 
goblet cells.41 Thus, in OVA-LPS-treated animals, the mucus 
discharge could facilitate the trapping of bacteria and prevent 
their attachment to the epithelial surface, while the altered motor 
responses would assist in their subsequent expulsion.42 
It is worthy to mention that LPS, per se, might be directly re-
sponsible for some of the changes in colonic contractility ob-
served in the present work. Indeed, low doses of LPS have been 
reported to enhance intestinal motility through mechanisms im-
plicating the enteric nervous system and the modulation of the 
production of several neuroimmune mediators (including IL-1, 
cyclooxygenase, and constitutive nitric oxide synthase) in mice 
and rats.43-45 Although not directly addressed, similar mecha-
nisms might be contributing to the changes observed in the pres-
ent study, with direct effects of LPS on local neuroimmune re-
sponses leading to alterations in smooth muscle contractility.
In summary, this study shows an interaction between luminal 
dietary antigens and components of the gut microbiota (LPS) 
leading to potential alterations in colonic motor activity. In partic-
ular, we show that a dysbiotic situation favours the sensitization 
against a luminal dietary antigen, namely OVA, and the gen-
eration of abnormal motor responses against that antigen. Similar 
mechanisms might contribute to the pathophysiology of IBS, 
where a significant proportion of patients show an altered micro-
biota and sensitivity to certain food components. Alterations of 
the microbiota might enhance/facilitate the local neuroimmune 
responses to specific food antigens leading to motor alterations 
reminiscent to those observed in IBS. Nevertheless, direct effects 
of LPS (independent of any microbial-related change) on local 
neuroimmune responses modulating colonic contractility and/or 
sensitization to OVA cannot be discarded. 
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